8-KAcquisitions & Dispositions

ELI LILLY & Co 8-K Report, Acquisition Completed (Jan 7, 2015)

Filed January 7, 2015For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 7, 2015, to provide updated financial guidance for 2014 and announce financial guidance for the upcoming year, 2015. The company also held a teleconference for analysts and media to discuss these projections. A key aspect of the filing is Lilly's use of non-GAAP financial measures, which they believe offer investors a clearer view of ongoing operations by excluding items such as significant acquisitions/divestitures and amortization of intangibles. These non-GAAP figures are intended to aid in meaningful period-over-period comparisons and trend identification. Investors should note that while Lilly emphasizes the utility of these non-GAAP measures for internal performance evaluation and external understanding of operational trends, these measures are presented as supplemental to, and not a replacement for, standard GAAP financial reporting. The prospective financial guidance for 2015 is also subject to potential adjustments for future events that are difficult to quantify, aligning with the nature of the non-GAAP adjustments.

Key Highlights

  • 1Eli Lilly issued updated financial guidance for 2014 and provided initial financial guidance for 2015.
  • 2The company held a teleconference on January 7, 2015, to discuss its financial outlook.
  • 3Lilly utilizes non-GAAP financial measures (e.g., non-GAAP earnings per share) in its reporting and guidance.
  • 4Non-GAAP measures exclude items such as the impact of acquisitions/divestitures and amortization of intangibles.
  • 5The company believes non-GAAP measures help investors evaluate ongoing operations and identify trends.
  • 6These non-GAAP measures are intended for supplemental analysis and not as a substitute for GAAP measures.
  • 7Prospective financial guidance is subject to future adjustments, as quantification of certain future events is not feasible.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide updated financial guidance for the fiscal year 2014 and to announce the company's financial guidance for the fiscal year 2015. It also informs about a related teleconference held for analysts and media.

Non-GAAP financial measures are financial metrics that exclude certain items from the standard GAAP (Generally Accepted Accounting Principles) reporting. Lilly uses them, such as non-GAAP earnings per share, to exclude the impact of significant acquisitions/divestitures, amortization of intangibles, and other unpredictable items. They believe these measures help investors better evaluate ongoing operations, make period-over-period comparisons, and identify operating trends.

Investors should consider these non-GAAP measures in addition to, but not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP. They provide a different perspective on the company's performance, focusing on operational aspects potentially masked by GAAP adjustments.

The prospective financial guidance for 2015 is subject to adjustment. Similar to the non-GAAP adjustments, future events may arise that are difficult to quantify and could impact the guidance. Lilly acknowledges this inherent uncertainty in forward-looking statements.